HOME >> BIOLOGY >> NEWS
Researchers study metabolic, cardiovascular effects of caffeine consumed with naringin

April 9, 2003 (San Diego, CA) -- If you are one of the millions of overweight Americans then your breakfast may be comprised of black coffee (five calories), dry toast (70 calories), and a grapefruit (60 calories for one-half). Many believe that grapefruit influences caffeine's effect on the body.

A flavonoid (plant pigment) compound found in grapefruit, naringin gives grapefruit its characteristic bitter flavor. Grapefruit processors attempt to select fruits with low naringin content, and often blend juices obtained from different grapefruit varieties to obtain the desired degree of bitterness. Naringin is believed to enhance our perception of taste by stimulating the taste buds; that's why some people consume a small amount of grapefruit juice before a meal.

But there are downsides to the healthy fruit.

Previous research has found that naringin interferes with enzymatic activity in the intestines thus slowing the breakdown of certain drugs and resulting in higher blood levels of the drug. A number of drugs that are known to be affected by the naringin in grapefruit include calcium channel blockers, estrogen, sedatives, medications for high blood pressure, allergies, AIDS, and cholesterol-lowering drugs. Consuming grapefruit or grapefruit juice may also extend caffeine levels and effects of caffeine.

While the effect of naringin on the metabolism of a drug can increase the drug's effectiveness, it can also result in dosages that are inadvertently too high. Therefore, many physicians do not recommend that patients take any drugs with grapefruit juice unless the interaction with the drug is known. In addition, the effects of drinking grapefruit juice is cumulative, which means that if you drank a glass of grapefruit juice daily with your medication for a week, the drug interaction would be stronger at the end of the week than at the beginning.

Flavonoids from grapefruit juice have been reported to affect hepatic metabolism
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-967-2751
American Physiological Society
9-Apr-2003


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: